Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Pharm Companies Focus On Microdosing Compounds

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers are turning increasingly to microdosing of compounds in humans to test how the drugs are absorbed and metabolized before subjecting them to clinical trials. Japan's Health Ministry established guidelines for the practice last year, following similar efforts in the United States and Europe. Eisai began conducting microdosing tests in Europe last year and now is doing joint research with 13 other firms, including Daiichi Sankyo, Mitsubisihi Tanabe Pharma and Ono Pharmaceutical, all working with research organizations. The head of Eisai's research and development section said the results have been "enormously useful." (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071311

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel